Skip to main content

ADVANCED

 

GENE THERAPY
SOLUTIONS

Our proprietary gene therapy manufacturing solutions help pioneering companies achieve high-titre, scalable and cost-effective viral vector production, helping to accelerate clinical success.

Advanced

PLASMIDS AND
CELL LINES

Optimised XAAV™ plasmid system including reconfigured rep-cap and minimised Ad5 helper plasmids improve AAV yield and quality. Cell line development services are underpinned by expertise in molecular biology and genetic engineering and supported by state of the art automation.

Advanced

TESSA: SCALABLE AAV PRODUCTION

Our proprietary Tet-enabled self silencing adenoviral (TESSA™) AAV manufacturing system delivers gene therapy pioneers highyield, high quality AAV in a scalable, contaminant, chemical and transfection free process.

Coming soon

PROMOTER
DISCOVERY

Proprietary bioinformatics aid the rational design of combinatorial promoter / enhancer libraries that we screen for optimal promoter combinations designed to your specifications. 

Advanced

TRANSIENT AAV PRODUCTION

Our industry leading technology platform provides flexible, high titre rAAV production. Our reconfigured Rep-Cap and modified Ad5 helper plasmids combined with a GMP banked clonal suspension HEK293 cell line offer gene therapy companies an improved AAV yield.

Coming soon

CAPSID
DISCOVERY

Proprietary bioinformatics and TESSA™ technology enable the generation of a genotype : phenotype linked AAV library we can screen for novel functional capsids with your desired infectivity and specificity.

Our industry leading biomanufacturing solutions help
pioneering companies scale up and advance clinical
manufacture of their breakthrough cell and gene therapies

RYAN CAWOOD, CHIEF SCIENTIFIC OFFICER, OXGENE & WuXi ATU

 

 

Get the best results with comprehensive
technical support from our expert scientists.

 

Our Publications

 

Are you ready for GMP Manufacture?

WuXi Advanced Therapies is a global Contract Testing, Development
and Manufacturing Organization (CTDMO) dedicated to accelerating
progress and time to market for cell and gene therapies.

×